Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage II Lung Cancer AJCC v8: full-pipeline trial registry
14 of 25 indexed Stage II Lung Cancer AJCC v8 trials are currently recruiting.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 14 currently recruiting · #652 of 28,707 conditions by registered trial count
Stage II Lung Cancer AJCC v8: 25 US clinical trials tracked, 14 recruiting.
Stage II Lung Cancer AJCC v8 is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition stage-ii-lung-cancer-ajcc-v8
OPEN 14 | RECR 56% | LATE 6 | EARLY 9 | RANK #652 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Celiac Disease (56% recruiting · 25 trials)
Stage II Lung Cancer AJCC v8 lists 14 open slots (56% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage II Lung Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage II Lung Cancer AJCC v8 is recruiting above its size-band peers.
14 of 25 indexed trials (56%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage II Lung Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 7 of 25 trials (28%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage II Lung Cancer AJCC v8 enrolment sits around 98 participants.
Median target enrolment is 98 among the 25 trials that report a genuine target (sentinel values excluded). 13 of those (52%) plan for fewer than 100 participants.
-
Stage II Lung Cancer AJCC v8 research is mostly interventional.
24 interventional and 1 observational studies make up this index (96% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
NCT04267848
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT06632327
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
M.D. Anderson Cancer Center
NCT03948100
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
NCT06498635
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Roswell Park Cancer Institute
NCT04067830
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
Roswell Park Cancer Institute
NCT05292521
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Thomas Jefferson University
NCT05502523
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Mayo Clinic
NCT06122064
New York Better Breathing Study
Roswell Park Cancer Institute
NCT06869447
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Northwestern University
NCT05802186
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Mayo Clinic
NCT06918132
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
NCT04789681
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Rutgers, The State University of New Jersey
NCT04751747
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT05136846
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
NCT03811002
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04214262
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
City of Hope Medical Center
NCT04428905
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
NCT04946279
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
M.D. Anderson Cancer Center
NCT04430725
Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment
M.D. Anderson Cancer Center
NCT03731585
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
NCT04310020
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
NCT03634241
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04505267
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
M.D. Anderson Cancer Center
NCT04013542
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
University of Southern California
NCT05340309
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage II Lung Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage II Lung Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage II Lung Cancer AJCC v8 page
25 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Stage II Lung Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage II Lung Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage II Lung Cancer AJCC v8 condition card totals 25 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.